Skip to main content
letter
. 2021 Feb 3;68(6):e28915. doi: 10.1002/pbc.28915

TABLE 1.

Demographic and clinical characteristics of patients with COVID‐19, treatment and outcome

n %
Median age (range) (years) 6 (0.3‐17.8)

Sex

Male

Female

  • 33

  • 18

  • 65

  • 35

Type of cancer (total number of cancer patients with cancer)

Leukemia a

Lymphomas and reticuloendotehelial tumors (HL, NHL, LCH, HLH) b

Brain tumors c

Neuroblastoma

Bone tumors d

Soft tissue sarcomas e

Other solid tumors f

  • 51

  • 26

  • 5

  • 5

  • 4

  • 3

  • 3

  • 5

  • 51

  • 9.8

  • 9.8

  • 7.8

  • 5.9

  • 5.9

  • 9.8

Disease status

During primary treatment

Relapse/refractory disease

Stem cell transplantation

At diagnosis

End of treatment

  • 28

  • 7

  • 6

  • 6

  • 4

  • 55

  • 14

  • 12

  • 12

  • 7.8

Diagnosis

PCR, clinic and radiologic positivity

PCR positivity only (contact with positive person)

PCR positivity at screening before surgery, radiotherapy, or SCT

PCR negative, clinical and radiological positivity

  • 23

  • 13

  • 6

  • 9

  • 45

  • 26

  • 12

  • 18

Definite case

Probable case

  • 40

  • 11

  • 78

  • 22
Contact history 24 47

Most frequent symptoms and findings

Asymptomatic

Fever

Cough

Other respiratory system findings (tachypnea, dyspnea, hypoxemia)

  • 19

  • 29

  • 21

  • 16

  • 37

  • 59

  • 41

  • 31

Organs and systems involvement

Respiratory system (upper respiratory tract infection + pneumonia)

Gastrointestinal system g

Central nervous system

Musculoskeletal system

Skin

  • 33 (7 + 26)

  • 9

  • 4

  • 3

  • 2

  • 65

  • 18

  • 7.8

  • 5.9

  • 3.9

Radiological findings

Normal

Bilateral diffuse or patchy ground glass opacity

Diffuse or patchy pneumonic infiltration or consolidation

Pneumonic infiltration and ground glass opacity

Pleural effusion

ARDS

  • 25

  • 7

  • 11

  • 9

  • 3

  • 1

  • 49

  • 14

  • 22

  • 18

  • 5.9

  • 2.0

Laboratory findings

Neutropenia

Lymphopenia

Anemia

Thrombocytopenia

CRP (mg/dL) median (range)

Increased CRP (number of patients with increased CRP/no. tested)

D‐dimer median (range)

Increased D‐dimer(number of patients with increased D‐dimer/no. tested)

  • 26

  • 23/45

  • 33/47

  • 25/47

  • 11.4 (0‐270)

  • 28/48

  • 400 (33‐6530)

  • 13/31

  • 51

  • 51

  • 70

  • 53

  •  

  • 58

  •  

  • 42

Severity of disease

Asymptomatic/mild

Moderate

Severe

Critical

  • 25

  • 15

  • 2

  • 9

  • 49

  • 29

  • 3.9

  • 18
Number hospitalized h 38 75
Length of hospitalization (median, range) (day) 11 (2‐45) (2‐45)
Necessity of ICU 9 18
Necessity of intubation 3 5.9

Treatment

No treatment

Azitromycine

Hydroxychloroquine

Hydroxychloroquine + azitromycine

Azitromycine + antivirals i

Hydroxychloroquine + azitromycine + antivirals i

Convalescent plasma (in addition to other medication)

Mesenchymal stem cell + tocizulumab (in addition to other medication)

  • 10

  • 10

  • 4

  • 14

  • 1

  • 3

  • 1

  • 20

  • 20

  • 7.8

  • 27

  • 2.0

  • 5.9

  • 2.0
Interruption/delay of chemotherapy 32 63
Treatment delay (median, range) (days) 15 (3‐45)
Length of PCR positivity (median, range) (days) 7 (2‐17)

Outcome of disease

Recovery

Death

  • 50

  • 1

  • 98

  • 2.0

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ARDS, acute respiratory distress syndrome; BMT, bone marrow transplantation; GIS, gastrointestinal system; HL, Hodgkin lymphoma; HLH, hemophagocytic lymphohistiocytosis; ICU, intensive care unit; LCH, Langerhans cell hystiocytosis; MDS, myelodysplastic syndrome; NHL, non‐Hodgkin lymphoma.

a

ALL, n = 18; AML, n = 7; MDS, n = 1.

b

HL, n = 2; NHL, n = 1; HLH, n = 1; LCH, n = 1.

c

Medulloblastoma, n = 4; atypical teratoid rhabdoid tumor, n = 1.

d

Ewing Sarcoma, n = 2; osteosarcoma, n = 1.

e

Rhabdomyosarcoma, n = 2; desmoid fibromatosis, n = 1.

f

Germ cell tumors, n = 2; hepatoblastoma, n = 1; Wilms tumor, n = 1; metastatic carcinoma, n = 1.

g

Presented with diarrhea, colitis, and gastrointestinal bleeding.

h

Six were already hospitalized for other reasons (such as diagnostic workup and surgery) and they received COVID‐19 diagnosis during this time.

i

Antivirals (favipiravir, lopinavir).